Schott Pharma, a German drug containment and delivery systems manufacturer, has completed a $60M+ expansion at its Lebanon, Pennsylvania facility, boosting domestic production of standard and sterile ready-to-use (RTU) glass vials. The move strengthens US pharmaceutical packaging supply chains and supports growing demand for biologics and injectable therapies, a key signal for medical aesthetics buyers sourcing high-quality primary packaging for injectables.
Expansion details and capacity boost
The expansion, partly funded by the US Biomedical Advanced Research and Development Authority (BARDA), adds new production lines for standard borosilicate glass vials and sterile RTU vials. It also upgrades infrastructure with advanced automation and converting technologies to improve manufacturing efficiency. Annual capacity for standard vials has increased significantly, while local capacity for high-value solutions used in biologics, vaccines, and emergency medicines has more than tripled.
Strategic product lines
The Lebanon site is now one of only two Schott Pharma facilities globally producing EVERIC pure vials, which offer high chemical durability and uniform inner surfaces for improved drug stability. It is also the company's sole site manufacturing adaptiQ pre-washed, pre-sterilized RTU vials. These RTU configurations reduce manual preparation steps for pharmaceutical manufacturers and contract manufacturing organizations, enhancing filling flexibility and regulatory compliance for sterile injectable production.
Industry context and buyer implications
This expansion aligns with rising demand for high-value drug containment systems driven by growth in biologics, biosimilars, GLP-1 therapies, antibody-drug conjugates (ADCs), and other temperature-sensitive injectables. For medical aesthetics distributors and clinic buyers, the increased US-based capacity for RTU vials and high-durability glass packaging supports reliable sourcing of primary packaging for injectable aesthetic products, reducing supply chain risks tied to overseas dependencies.
What buyers should watch
Medical aesthetics buyers should monitor Schott Pharma's expanded RTU vial production as it may improve lead times and availability for sterile packaging used in dermal fillers, neurotoxins, and other injectables. The local-for-local manufacturing strategy also signals potential cost stability and regulatory ease for US-based clinics and distributors seeking compliant packaging solutions.
Source: Read the original report | Published: June 06, 2026